In this randomized pilot clinical trial, dolutegravir plus lamivudine was noninferior to continuation of standard 3-drug maintenance antiretroviral therapy. There was no emergence of drug resistance in the participant who experienced virologic failure while receiving dolutegravir plus lamivudine.

中文翻译：

---

Dolutegravir Plus拉米夫定在一项随机试验中通过第48周维持人类免疫缺陷病毒-1的抑制

在这项随机的临床试验中，dolutegravir加lamivudine的疗效不逊于标准的3种药物维持抗逆转录病毒疗法。在接受dolutegravir加拉米夫定的同时发生病毒学失败的参与者中未出现耐药性。